A neuroscience lab at the Fralin Biomedical Research Institute, led by Matthew Weston, studies how genetic differences shape neural inhibition and excitation to drive childhood epilepsies, aiming to identify new treatments.

Genetic mutations are a major driver of these treatment-resistant epilepsies, motivating ongoing research into their genetic roots.

Weston’s work focuses on genetic mutations that cause treatment-resistant epilepsy in children, affecting about half a million U.S. youths, and seeks how variations alter neural balance to inform future therapies.

This episode is part of a broader effort to engage the public with scientific research through accessible discussions and expert explanations of biomedical topics.

Epilepsy in children with treatment-resistant seizures carries higher risks of death, learning challenges, and social-emotional difficulties, underscoring the need for better therapies.

Overall, epilepsy affects roughly half a million U.S. children with treatment-resistant seizures, highlighting the gravity of the condition.

The podcast episode Big Science, Small Pod features Weston describing how seizures arise from brain activity and how genetic variations disrupt the balance between inhibition and excitation.

In the episode, Weston explains brain activity during seizures and outlines his lab’s efforts toward developing new treatments for pediatric epilepsy.

The podcast series aims to demystify questions about the human body, health, and disease by sharing insights from researchers at the Fralin Institute and how research translates into disease treatment.

Weston’s overarching goal is to translate seizure biology into tangible patient-care improvements that enhance life outcomes for children with epilepsy.

Ultimately, the aim is to convert scientific understanding into actionable care to better outcomes for affected children.